摘要
随着临床研究的深入,抗血管内皮生长因子(vascular endothelial growth factor,VEGF)抗体的靶向治疗越来越受到重视,其中贝伐单抗(bevacizumab,BV)成为关注的焦点,并于今年2010年5月在中国成功上市。本文就BV在转移性结直肠癌(metastatic colorectal cancer,mCRC)、非小细胞肺癌(non-small cell lung cancer,NSCLC)、转移性乳腺癌(metastatic breast cancer,mBC)及转移性肾细胞癌(metastatic renal cell carcinoma,mRCC)的靶向治疗中的研究进展作一综述。
Recently,more and more researchers have focused their interests on the anti-vascular endothelial growth factor（VEGF） antibody-targeted therapy.Bevacizumab（BV） has become one of the most important agents used worldwide,and it was approved for the market as a new targeted agent in May 2010 in China.This review summarizes the clinical advancements in the targeted therapy with BV in metastatic colorectal cancer（mCRC）,non-small cell lung cancer（NSCLC）,metastatic breast cancer（mBC） and metastatic renal cell carcinoma（mRCC）.
出处
《肿瘤》
CAS
CSCD
北大核心
2011年第4期379-384,共6页
Tumor
关键词
肿瘤
各部位
结直肠肿瘤
癌
非小细胞肺
乳腺肿瘤
肾肿瘤
血管内皮生长因子类
肿瘤治疗方案
Neoplasms by site
Colorectal neoplasms
Carcinoma
non-small cell lung
Breast neoplasms
Kidney neoplasms
Vascular endothelial growth factors
Antineoplastic protocols
